Cutaneous antifungal therapy in AIDS: Summary of an International Summit

Infectious Diseases in Clinical Practice

Volumn 5, Issue 6, 1996, Pages 359-370

  Elewski, Boni E ^a   Hay, Roderick J ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; AMOROLFINE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; CLIOQUINOL; CLOTRIMAZOLE; DIIODOHYDROXYQUIN; ECONAZOLE; FLUCYTOSINE; GRISEOFULVIN; HALOPROGIN; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; NYSTATIN; OXICONAZOLE; POTASSIUM IODIDE; PYRITHIONE ZINC; SELENIUM SULFIDE; SODIUM THIOSULFATE; SULCONAZOLE; TERBINAFINE; TERCONAZOLE; TINVER; TIOCONAZOLE; TOLNAFTATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VYTONE; ZINCON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; GENDER; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOSIS; OPPORTUNISTIC INFECTION; REVIEW; SKIN INFECTION; SOCIOECONOMICS;

EID: 0029778915     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199608000-00004     Document Type: Review

References (12)

1. Hirsch M, Kaplan J. The biomedical impact of the AIDS epidemic. In: Broder S, Merigan T, Bolognesi D, editors. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:3-123.
2. Piot P, Laga M. Epidemiology of AIDS in the developing world. In: Broder S, Merigan T, Bolognesi D, editors. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:109-32.
3. Anderson R, May R, Boily M, et al. The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDS. Nature 1991;352:581-9.
4. Bugingo G, Ntilivamunda A, Nzaramba D, et al. Etude sur la seropositivity liee a l'infection au virus d'immunodeficience acquise au Rwanda. Rev Med Rwand 1988;20:37-42.
5. Masur H, Ognibene F, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
6. Wheat LJ, Hafner R, Wulfsohn M, et al., NIAID Clinical Trials Group, Mycoses Study Group. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6.
7. Morris S, Wheat J, McKinsey D, et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994;96:504.
8. Masur H, Ognibene F, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
9. Denning D, Amper N, Stevens D. Opportunistic mycoses in HIV infection: aspergillosis and coccidioidomycosis. HIV Adv Res Ther 1994;4:22-9.
10. Stevens D. Management of systemic manifestations of fungal disease in patients with AIDS. J Am Acad Dermatol 1994;31:S64-S67.
11. Fish D, Ampel N, Galgiani J, et al. Coccidioidomycosis during human immunodeficiency virus infection. Medicine (Baltimore) 1990;69:384-91.
12. Pursell K, Telzak E, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis 1992;14:141-8.